Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 502

The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.

Genomic and phenotypic heterogeneity in prostate cancer

Open access
Haffner, Michael C., Zwart, Wilbert, Roudier, Martine P., True, Lawrence D., Nelson, William G., Epstein, Jonathan I., De Marzo, Angelo M., Nelson, Peter S., Yegnasubramanian, Srinivasan·2021·Nature Reviews Urology

Abstract

From a clinical, morphological and molecular perspective, prostate cancer is a heterogeneous disease. Primary prostate cancers are often multifocal, having topographically and morphologically distinct tumour foci. Sequencing studies have revealed that individual tumour foci can arise as clonally distinct lesions with no shared driver gene alterations. This finding demonstrates that multiple genomically and phenotypically distinct primary prostate cancers can be present in an individual patient. Lethal metastatic prostate cancer seems to arise from a single clone in the primary tumour but can exhibit subclonal heterogeneity at the genomic, epigenetic and phenotypic levels. Collectively, this complex heterogeneous constellation of molecular alterations poses obstacles for the diagnosis and treatment of prostate cancer. However, advances in our understanding of intra-tumoural heterogeneity and the development of novel technologies will allow us to navigate these challenges, refine approaches for translational research and ultimately improve patient care. This Review summarizes the manifestations of inter-tumoural and intra-tumoural heterogeneity in primary and metastatic prostate cancer, emphasizing the contribution of genomics studies and discussing the importance of phenotypic changes. The authors also critically discuss the implications for clinical management and research. Primary prostate cancers are often multifocal with spatial and morphologically distinct tumour foci. Individual tumour foci can show non-overlapping truncal genomic alterations, suggesting that multiple clonally distinct cancers can arise in a given patient. Intra-tumoural and inter-tumoural heterogeneity present within the prostate gland poses diagnostic challenges. Despite the multiclonality of primary cancer, clonal bottlenecks imposed by the metastatic process and further by therapeutic interventions seem to select for a single dominant clone in lethal metastatic prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41585-020-00400-w

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 175 references

Cited by

See all 502

Metadata

Authors
Haffner, M. C., Zwart, W., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., De Marzo, A. M., Nelson, P. S., & Yegnasubramanian, S.
Venue
Nature Reviews Urology
Published
2020-12-16
Volume
18
Issue
2
Pages
79-92
ISSN
  • 1759-4812 (ISSN-L)
  • 1759-4820
OpenAlex
W3111149356
Cited by
502
References
175
FWCI
10.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic and phenotypic heterogeneity in prostate cancer. https://app.cochat.ai/papers/10.1038/s41585-020-00400-w
The paper
Haffner, M. C., Zwart, W., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., De Marzo, A. M., Nelson, P. S., & Yegnasubramanian, S. (2021). Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews Urology. https://doi.org/10.1038/s41585-020-00400-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.